MedTech Innovator

Aqua Medical, Inc. develops a disruptive, vapor-based, endoscopic, ablation technology to treat gastrointestinal (GI) disease and prevent GI cancers. Its ablation technology includes high temperature water vapor created by a radio frequency generator and delivered endoscopically through proprietary catheters to the GI tract. The company’s platform technology uses a vapor generator system with two catheter types to deliver treatment for multiple diseases throughout the GI tract. The company was incorporated in 2016 and is based in Santa Ana, California.

52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

Limax Biosciences transform tissue healing inside and outside the body.

ConKay Medical Systems is an early-stage medical device company focused on developing innovative solutions to address valvular regurgitation in patients suffering from progressive heart failure. The company's technology is centered around annular repair, which targets the primary cause of functional regurgitation while preserving the integrity of healthy leaflets. This approach aims to enhance the effectiveness of cardiovascular care, providing healthcare professionals with advanced tools to better manage this condition.

Digma Medical is a clinical stage medical device company established in 2013, focused on innovating treatments for Type-2 Diabetes and related metabolic syndromes, including NASH. The company is developing the DiaGone™, an endoscopic and disposable device that employs advanced laser technology to treat the duodenum without the need for an implant. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to use the DiaGone™ to enhance the body's ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and other metabolic conditions, thereby improving their overall quality of life and health outcomes. Supported by prominent venture capital firms, Digma Medical is dedicated to advancing effective therapies for diabetes management.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

Corveus Medical is focused on creating innovative solutions to prevent heart failure through the development of a neuromodulation device. This catheter-based technology aims to safely and effectively access nerve tissue, enabling nerve ablation for improved treatment outcomes. By employing minimally invasive methods, Corveus Medical seeks to alleviate both the clinical and economic burdens associated with heart failure, marking a significant advancement in the field of cardiac care. The company is committed to delivering consistent results and enhancing patient quality of life through its pioneering approach to heart failure treatment.

Woven Orthopedic Technologies is a medical device company based in Manchester, Connecticut, that specializes in developing orthopedic technologies aimed at improving patient care. Founded in 2013, the company focuses on enhancing the screw-to-bone interface to address challenges related to screw fixation in orthopedic procedures. Its innovative solutions utilize biopolymers and biotextile materials to increase surface area contact between screws and bone, thereby promoting bone healing and remodeling while enhancing fixation. The company aims to provide orthopedic surgeons with standardized, efficient, and accessible solutions that meet the diverse needs of patients. By addressing the most commonly used orthopedic implants, Woven Orthopedic Technologies strives to influence advancements in musculoskeletal care, ensuring that effective treatments are available to a wider population.

Discure Technologies is focused on creating a minimally invasive, implantable bioelectronic device aimed at treating degenerative disc disease (DDD). This innovative device employs a novel bioelectric technique that addresses the root cause of DDD, allowing physicians to alleviate pain and restore normal disc function in patients. By promoting healing of the affected discs, Discure seeks to improve the quality of life for individuals suffering from this condition.

Neurovalens Limited is a company based in Ballymena, United Kingdom, that specializes in the development of medical devices grounded in neuroscience, bioscience, and neurophysiology. Founded in 2013, the company focuses on creating non-invasive neurostimulation products to address significant health challenges, particularly obesity. Notable products include Stimu Slim and Modius, which are electronic headsets designed to promote weight loss through transdermal activation of brainstem and hypothalamic functions. These devices aim to enhance autonomic function and circadian regulation, offering healthcare providers drug-free alternatives to improve patient health outcomes. Neurovalens has also received support from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme, which will facilitate research and development to enhance the company's competitiveness.

Gradient Denervation Technologies develops a endovascular catheter-based medical device to treat pulmonary hypertension. Its medical device aims at reducing pulmonary vascular resistance and improving cardiovascular hemodynamics. The company was incorporated in 2019 and is based in Paris, France.

Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.

Epineuron Technologies, Inc. is a medical device company based in Hamilton, Canada, focused on developing innovative treatment solutions for peripheral nerve injuries. Founded in 2016, Epineuron is pioneering bioelectronic medicine with a mission to set new standards in nerve repair and regeneration. The company is creating a range of surgical solutions, including an electroceutical device that provides electrical stimulation to enhance the natural healing processes of injured peripheral nerves. By accelerating nerve regeneration, Epineuron aims to offer patients advanced care options and aims to establish itself as a leader in the field of bioelectronic nerve therapy.

SymPhysis Medical focuses on developing innovative medical technologies aimed at treating chronic diseases, with an emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, addresses malignant pleural effusion (MPE), a common complication in late-stage cancer patients that can lead to severe shortness of breath and chest pain. This therapeutic device is designed for home use, effectively draining excess fluid from the pleural space. By utilizing an active component that enhances fluid removal efficiency, releaze alleviates distressing symptoms and improves treatment accessibility for patients requiring indwelling pleural catheter (IPC) therapies.

RevBio is commercializing an injectable, self-setting bone adhesive that can bond bone to bone and bone to metal to stabilize implant devices. Over time, the adhesive biodegrades and is replaced by new bone. This unique material will reduce the duration and complexity of medical procedures, allow for more minimally invasive surgeries, and will improve patient outcomes by reducing recovery time and the overall cost of care.

Liquet Medical is a medical device development company focused on improving the treatment of vascular disease through innovative localized drug delivery methods. The company's flagship product, the Versus Catheter, features a dual-tip infusion design, real-time pressure monitoring, and a flow-directed placement balloon. These advancements aim to enhance patient outcomes and promote healthcare sustainability by providing healthcare professionals with more effective tools for managing vascular conditions. Liquet Medical's commitment to developing patented technologies positions it as a significant player in the medical device sector.

ThermopeutiX is a privately held company that offers imaginative, innovative and economical solutions to unmet medical needs.

Orbit Genomics applies its proprietary OrbiSeq technology platform to aid in diagnosing and ultimately preventing complex diseases.

ZKR Ortho is engaged in developing innovative medical devices and procedures aimed at alleviating chronic knee pain associated with Condromalacia Patellae, a condition characterized by the degeneration of cartilage and inflammation beneath the patella. This condition affects millions, often leading individuals to delay intervention due to the invasiveness of traditional surgical solutions. ZKR Ortho's approach offers a minimally invasive implant procedure that unloads the patellofemoral joint by elevating the patella tendon, thereby realigning the knee cap towards healthier cartilage. This method not only relieves pain but also promotes mobility and may reduce the necessity for knee replacement surgeries. Founded by Dr. Jeffrey Halbrecht, a leader in minimally invasive arthroscopic techniques, the company holds multiple patents and has developed prototypes for its devices. Currently, ZKR Ortho is in the process of raising capital to support product trials.

HEPTA Medical develops a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and ablates pulmonary nodules, the precursor of lung cancer, without the need for surgery or radiation.

EndObetes is a medical device company that develops an endoscopically food delivery solution for treating obesity and diabetes. The company's device shunts food directly from the esophagus to the intestine, bypassing the stomach and duodenum, much like gastric bypass surgery, enabling people to get access to a durable, safe and effective non-surgical treatment for obesity and diabetes. It was founded in 2015 and is based in New York, New York.

Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

Venari Medical Limited, founded in 2018 and based in Galway, Ireland, develops innovative medical devices aimed at treating chronic venous diseases (CVD). The company's flagship product, BioVena, employs the body's natural healing processes to provide a more effective and less invasive treatment option for conditions such as varicose veins and venous ulcers. Venari Medical seeks to address the significant gap in treatment, as only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. Their technology not only offers a safer alternative to existing methods but also targets the underserved population of venous ulcer patients who currently rely on ineffective compression bandaging. By widening the indications for superficial venous ablation, Venari Medical aims to reduce the annual costs associated with venous ulcers, which total approximately $33 billion for insurers in these regions. The company's commitment to patient-centered solutions positions it to disrupt traditional treatment practices that have seen limited innovation in recent years.

Koya Medical, Inc. is a company based in Oakland, California, founded in 2018. It focuses on developing a connected wearable platform designed to address the significant unmet needs in the treatment of cancer-related chronic lymphedema and venous diseases. The technology aims to provide a drug-free solution for patients suffering from these conditions, enhancing their quality of life through innovative medical devices.

Bone Health Technologies, Inc. is focused on creating innovative medical devices to combat low bone mass conditions such as osteopenia and osteoporosis. The company's flagship product, OsteoBoost, is a wearable device designed for the lower back that utilizes whole-body vibration technology to deliver gentle mechanical stimulation. This stimulation mimics the effects of weight-bearing exercise, promoting bone health by activating stem cells to strengthen bone density. Founded in 2018 and headquartered in San Francisco, California, Bone Health Technologies aims to provide a safe and effective non-drug intervention for individuals at risk of bone mass deterioration.

Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.

Auctus Surgical is focused on innovative solutions for treating pediatric scoliosis through its dynamic vertebral body tethering system. This system is designed for non-fusion scoliosis correction, allowing for non-surgical adjustments over time. By incorporating dynamic magnetic technology, Auctus enables surgeons to implement a spinal tethering system that facilitates growth modulation without the need for traditional surgical interventions. In addition to its primary product, Auctus has also licensed technology related to magnetically adjustable growing rods, which can be utilized for both pediatric scoliosis treatment and limb lengthening. This approach aims to improve outcomes for young patients by providing a less invasive alternative to conventional surgical methods.

TrueCath is a medical device company creating the next generation of peripheral IV auto-catheters. Truecath is of similar size, shape, and manufacturing cost to the currently used PIVC systems. It can also be placed with only one hand and is mostly independent of operator skill level. Importantly, Truecath will prevent the most common cause of missed first attempt PIVC placement, which is penetration through the back wall of the vessel and catheter failure. This key advantage will decrease the multitude of complications involved with PIVC placement, improve patient comfort and reduce healthcare costs. The company was founded in 2016 and is headquartered in Camarillo, California.

X-COR Therapeutics, based in Allston, Massachusetts, is a medical device company focused on developing innovative CO2 removal devices for patients experiencing acute respiratory failure. Founded in 2017, the company has created a novel consumable hybrid cartridge that enables the removal of excess carbon dioxide from a patient's blood using ultra-low blood flows of less than 300 ml/min. This approach is less invasive and allows for easier placement by nursing staff, making the therapy more accessible and affordable compared to traditional extracorporeal devices, which typically require higher blood flow rates and specialized medical personnel. X-COR's technology is supported by a machine-learning-based control algorithm and is designed to integrate smoothly with existing medical infrastructure, enhancing its usability in clinical settings. The company gained recognition as a runner-up in the 2018 Harvard President’s Innovation Challenge and participated in the MedTech Innovator and MassChallenge cohorts that same year.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Paragate Medical is a company based in Nazareth Illit, Israel, specializing in the design and development of implantable devices aimed at providing continuous relief for patients suffering from congestive heart failure and fluid overload conditions related to heart and kidney failure. The company's innovative solutions address the clinical symptoms associated with these health issues, ultimately aiming to alleviate the associated healthcare burden for patients.

Ictero Medical is a medical devices company focused on developing innovative solutions for patients with gallstone disease. The company has created a minimally invasive gallbladder ablation tool that allows for the treatment of high-risk patients without the need for surgical removal of the gallbladder. This device can be utilized in interventional radiology suites and requires only minimal local anesthesia, thereby reducing the associated risks of traditional surgery. By offering a definitive treatment option, Ictero Medical aims to improve patient outcomes while minimizing complications related to gallbladder surgery.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, focused on enhancing the treatment options for patients with brain tumors. Founded in 2017, the company has developed GammaTile, an innovative medical device that integrates a biocompatible collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a conformable and bioresorbable solution that can potentially prevent disease progression and improve patient quality of life. GammaTile has received multiple patents and has shown promise in clinical trials, with significant improvements observed in patients treated at the Barrow Neurological Institute. This approach aims to revolutionize care for the estimated 176,000 individuals diagnosed with brain tumors annually in the United States.

ZetaGen Therapeutics Inc is a preclinical regenerative medicine company focused on developing innovative products for bone regeneration. Established in 2015 and based in Syracuse, New York, the company specializes in a small molecule-based osteoinductive technology that activates a novel molecular pathway to promote bone growth. ZetaGen's product offerings aim to address a variety of bone-related injuries, procedures, and diseases, providing potential advancements in treatment efficacy. By combining drug and device elements, the company strives to improve outcomes for patients, healthcare providers, and payors alike.

AxioSonic is a developer of non-invasive treatment intended to treat chronic sinusitis. It uses a proprietary multimodal frequency system to treat facial pain and reduce symptoms of chronic sinusitis without the use of any medication, enabling healthcare providers to improve pain scores, sinus symptom scores, and patient outcomes. The company was founded in 2015 and is headquartered in Effingham, Illinois.

Deton Corp. is a diagnostics technology company based in Pasadena, California, founded in 2011. It specializes in developing innovative solutions for measuring and controlling lower respiratory infections. The company's flagship product, the aerosol biopsy solution, captures aerosol droplets expelled during coughing, allowing for the extraction of genetic information from within the lungs. This technology enables the collection of samples from the lower respiratory tract, facilitating the diagnosis of infections and providing valuable insights into the growth of fungal and bacterial microbes. Through its advancements, Deton aims to enhance the understanding and treatment of lung diseases by delivering complete and timely lung health information.

Impleo Medical is a developed a proprietary bulking agent therapy for Gastroesophageal Reflux Disease in medical devices

Medable, Inc. operates a cloud-based platform that facilitates decentralized clinical trials, enabling healthcare providers, biopharma sponsors, and clinical research organizations to enhance trial design, recruitment, retention, and data quality. The platform integrates various digital tools and services, ensuring compliance with health regulations while improving patient access and experience. Key offerings include solutions for telemedicine, such as HIPAA-compliant video consultations and platforms for capturing clinical trial outcomes remotely. Medable's services support the creation of applications for mobile, desktop, and web use, addressing the needs of doctors, hospitals, and health technology companies. Founded in 2015 and headquartered in Palo Alto, California, Medable has been utilized in clinical trials across over 30 countries and 26 languages, contributing to more effective therapy delivery and patient outcomes.

Soundbite Medical Solutions Inc. is a cardiovascular medical technology company based in Montreal, Canada, specializing in the development and commercialization of innovative medical devices. Founded in 2013, the company focuses on creating a proprietary wire-based device and generator console that utilizes shockwave energy to treat chronic total occlusions (CTOs) within the cardiovascular system. This technology is designed to enhance vessel preparation for patients suffering from peripheral artery disease (PAD) and coronary artery disease (CAD), which collectively impact over 20 million individuals in the United States. Soundbite Medical Solutions aims to improve treatment outcomes for these patients through its advanced therapeutic solutions.

ODS Medical Inc. is a Montreal-based medical device company established in 2015, specializing in the design and manufacture of a proprietary Raman spectroscopy system for cancer detection. The company focuses on commercializing this advanced technology to enable real-time detection of tissue abnormalities across various clinical settings. By integrating innovative optical probes with sophisticated software powered by machine learning algorithms, ODS Medical aims to provide physicians with next-generation diagnostic tools. This approach enhances the sensitivity, specificity, and accuracy of medical diagnoses, ultimately empowering healthcare professionals to make critical decisions in real-time.

Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

PharmaJet, Inc. is a company that specializes in the development and marketing of needle-free injection devices for the vaccine delivery sector. Founded in 2005 and headquartered in Golden, Colorado, PharmaJet offers products under the Stratis and Tropis brands. These innovative devices utilize a narrow stream of fluid to deliver vaccines intramuscularly, subcutaneously, or intradermally without the use of needles. This technology aims to address significant issues associated with traditional needle-syringe methods, such as the risk of needle-stick injuries, potential needle reuse, cross-contamination, and the disposal of sharps waste. By providing a user-friendly and cost-effective alternative for fluid injection, PharmaJet's products enhance safety and comfort for both healthcare providers and patients, while also contributing to a positive return on investment in the immunization market.

The Otricath™ introduces a new perspective on therapy delivery. The platform technology delivers cancer-fighting agents to solid tumors with unparalleled control, predictability, and safety for optimal therapeutic benefit and minimal systemic toxicity.

Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Founded in 2013, the company specializes in developing advanced electrosurgical devices, particularly focusing on radiofrequency ablation technology. One of its key innovations is the Sira™ device, a saline-assisted intraoperative radiofrequency ablation tool that employs bipolar current to create a controlled zone of ablation. Sira's unique design, featuring a saline microinfusion system, enhances contact with target tissue and is compatible with standard electrosurgical generators already utilized in operating rooms. This technology offers surgeons a new, effective option for intraoperative ablation of soft tissue, promoting ease of use and adoption in surgical practices.

Palmm is a venture capital investment firm that specializes in developing innovative medical devices. One of its key products addresses the issue of excessive sweating, providing a convenient at-home treatment that targets specific body parts, such as the hands. The device employs a mild electrical current delivered through wearable garments to deactivate sweat glands, offering relief for several weeks. This solution aims to help individuals overcome the embarrassment associated with profuse sweating, allowing them to regain confidence in their everyday lives.

Selio is a simple, effective and patent protected technology. The Selio prototype has been rigorously tested in the lab and in subsequent acute pre-clinical in vivo studies with very positive results.

Revolutionary Medical Devices, Inc. began June 2014 where it received critical acclaim at the Post-Graduate Assembly (PGA) for Anesthesiology. RMD has received worldwide recognition from Key Opinion Leaders in Anesthesia and its technologies are living up to their name, “Revolutionary”. The company’s mission is to utilize current clinical literature to drive the development of innovative technologies to optimize patient positioning during airway management and anesthesia. RMD develops airway management products to significantly improve anesthesiologist workload, O.R. turnover time, and easier patient intubation.

Aqueduct Critical Care addresses the critical care problem of managing inter-cranial pressure. Its working prototypes demonstrate the ability to allow the patient to move, and minimize attention from nursing staff. Aqueduct Critical Care was founded in 2013 and is based in Bothell, Washington.

ITGI Medical is a bio-medical engineering company specializing in research and development, design, manufacture and distribution of high quality heterologous tissue covered stents for Cardiovascular and Neurovascular interventions. Their focus is on current technologies and applications that improve the standard of care for patients around the world in the fields of interventional Cardiology and Interventional Neuro-Radiology for the application in Coronary and neurological aneurysms, treatment of Fistulas, Saphenous Vein Graft occlusion (SVG Disease) and vascular perforations. Studies conducted prove that ITGI’s propriety technology can address these clinical problems in a safe and effective manner.

Evoke Medical is redefining the way orthopedic and spinal medical devices are researched, designed, and developed. They view things differently...They don't see the implant as a foreign object with the sole purpose of stabilizing or restoring motion. Instead, they view the implant as an integral part of the natural biochemical and biomechanical responses of the body postoperatively. They seek to mimic the bodies natural osteoinductive healing mechanisms via their implant designs.

Advanced Prenatal Therapeutics (APT) is developing a novel therapeutic device for treating preeclampsia by specifically removing harmful substances from the mother’s blood.

Synotrac is a novel, patent pending sensor technology that detects infection in vivo and alerts the patient and their physician in real time. The device quickly analyzes the body's immune response to give a dynamic picture of the joint's healing process, which enables detection of infection significantly earlier than other methods.

Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

VerteCore is a developer of an innovative orthopedic medical device aimed at relieving lower back pain. The company has created the VerteCore Lift, a patent-pending system that offers a non-surgical approach to spinal decompression. This device targets various sources of back pain, including compressed or bulging discs, sciatica, and functional scoliosis, using a dual support harness and a unique ratcheting mechanism for ease of use. By providing a convenient and mobile solution, VerteCore enables active individuals to find rapid relief from spinal discomfort without the need for hospitalization, medication, or surgical intervention.

Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

Avenda Health Inc. is focused on developing a minimally invasive treatment for prostate cancer through its artificial intelligence-based focal laser ablation system. This innovative technology includes a fiber-optic laser and a disposable sensor, which work together with a feedback control system to provide precise treatments. The system integrates prostate images and biopsies using MRI-ultrasound fusion for guidance, allowing procedures to be performed under local anesthesia. Avenda Health aims to deliver safe, effective, and cost-efficient alternatives for patients, enhancing their quality of life while undergoing outpatient treatment. Founded in 2017, the company is headquartered in Santa Monica, California.

Abreos Biosciences develops lateral flow assays that measure the activity of high-value biologics. Its simple devices can be used for quality assurance, pharmacokinetic monitoring, and authentication in field, forensic, or point of care settings. We deliver value by enhancing brand protection, improving patients’ outcomes, and enabling rapid authentication for counterfeit prevention and end-user confidence. The company was founded in 2013 and headquartered in San Diego, California.

OpiSafe is a provider of platforms that manage the opioid response for various stakeholders, including prescribers, dispensers, public health agencies, first responders, and the general public. The company offers an opioid intelligence system designed to optimize prescriptions and improve healthcare outcomes. Its technology facilitates communication between patients and their care providers through a mobile application, allowing for more effective recovery and enhanced patient care. OpiSafe aims to bridge the gap between the opioid epidemic and the necessary solutions to address it.

PeriCor provides minimally invasive alternatives to infants, children and adults who require interventions including pacemakers, defibrillators or cardiac ablation procedures.

Harbor MedTech, Inc. is a regenerative medicine company focused on developing and commercializing tissue regeneration products. Founded in 2010 and based in Irvine, California, the company offers a range of innovative solutions including Architect, an extracellular collagen matrix designed for managing various types of wounds such as diabetic ulcers, pressure sores, and surgical wounds. Additionally, Harbor MedTech provides NeuvoCell, a wound therapy specifically for chronic wounds, alongside products aimed at hernia and joint repair, orthopedic soft tissue repair, breast reconstruction, and urogynecological repair. Utilizing its BriDGE platform, the company is expanding its product pipeline to address needs in dermatology, general surgery, and plastic surgery. Harbor MedTech also maintains a strategic partnership with Edwards Lifesciences to enhance its offerings in the market.

HemaFlo Therapeutics, Inc. is an early stage company founded to commercialize a novel new device for the treatment of acute kidney injury and other ischemic conditions. The device is a very dilute solution of drag-reducing polymer (DRP) that is simply delivered intravenously to patients. Drag-reducing polymers have been studied in animals since the mid-1970’s and have shown dramatic benefits in disease models such as heart attack, hemorrhagic shock, diabetes, and atherosclerosis. The work has received little attention because the mechanism of action was unknown until just recently. HemaFlo Therapeutics has shown that drag-reducing polymers can be used to treat a very common and deadly condition that has a very attractive commercialization pathway. Acute kidney injury has no effective treatment and there are as many new cases in the US each year as for heart attacks, strokes, and cancer combined! Acute kidney injury is not widely perceived to be a serious problem because most cases occur in the hospital as a consequence of other diseases or procedures, resolve in a week or two, and the deaths are coded as heart failure (loss of regulation of electrolytes), respiratory failure (loss of regulation of fluids), or sepsis.

2Morrow, Inc. is a digital health company based in Kirkland, Washington, that specializes in evidence-based behavioral change programs and applications. Founded in 2012, 2Morrow's offerings include SmartQuit, a smoking cessation program grounded in Acceptance and Commitment Therapy, My Pocket Coach, a platform for personal goal setting and habit formation, and Healthy Habits, designed to help individuals develop positive habits or eliminate detrimental ones. The company collaborates with employers, health plans, states, and wellness programs to make its programs accessible to those in need through digital platforms. By integrating technology with behavioral science, 2Morrow addresses significant health issues such as smoking, weight management, stress, and chronic pain, aiming to improve individual health outcomes.

Nexeon MedSystems is a bioelectronics company developing active medical devices for the treatment of chronic medical conditions. The solutions we're developing are a unique blend of traditional device technologies such as electronics, software, mechanical engineering, and material science, as well as pharmaceuticals, protein chemistry, and cell biology.

NovaGray is focused on creating advanced companion diagnostic tests designed to enhance radiation therapy planning. The company develops biomarker-based tests that evaluate patients' sensitivity to radiation through a single blood sample. This approach allows healthcare practitioners to tailor treatment plans, including dosage and session sequencing, based on individual patient profiles. By personalizing standard treatments, NovaGray aims to improve patient outcomes while also reducing both complication and overall treatment costs.

Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.

Adhesys Medical specializes in the development and manufacture of innovative polyurethane-based surgical adhesives designed for diverse applications both on the skin and internally. Their products utilize a unique polyurethane technology that distinguishes them from existing options in terms of ease of use, flexibility, biodegradability, and performance in wet environments. These advanced surgical sealants aim to enhance surgical procedures, improve patient comfort, and ultimately save lives by providing effective and reliable solutions for healthcare professionals.

PreDxion Bio is a precision medicine diagnostics company that provides ICU doctors with actionable patient immune function data. The company offers MicroKine, a diagnostic tool that measures patients’ immune responses. It enables doctors to identify up to six cytokine proteins using small blood volumes. Using this technology, physicians are able to tailor ICU treatments to each patient's needs. Founded in 2016, PreDxion Bio is based in Ann Arbor, Michigan.

Madorra Their goal is empowering women to live fuller, healthier lives. Madorra is working towards changing the paradigm for treating vaginal dryness, by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. They are focused on giving post-menopausal women and breast cancer survivors the power to choose the non-hormonal treatment option they want.

SilverCloud Health Limited is a provider of online therapeutic solutions aimed at improving mental wellness. The company develops a platform that offers tailored clinical programs addressing various mental health issues, including emotional health. Founded in 2011 and headquartered in Boston, Massachusetts, with additional offices in Dublin, Ireland, and London, United Kingdom, SilverCloud Health delivers evidence-based digital therapies that enhance user engagement and reduce dropout rates compared to traditional online therapeutic products. By serving the healthcare, medical, and pharmaceutical sectors, SilverCloud Health enables individuals to access professional support quickly and affordably, promoting overall mental health and well-being.

Linear Health Sciences is a medical device company creating products for various types of medical tubing based on its proprietary, breakaway safety-valve technology. This platform technology is designed to improve the healthcare experience for patients, caregivers, and healthcare facilities. The company has made substantial progress toward global patent protections and FDA clearance for the Orchid Safety Release Valve. There is a total addressable market of more than $1 billion annually for devices made by the company, which was founded by a physician and two engineers.

VETEX Medical is an Irish medical device company developing a revolutionary thrombectomy catheter to speedily extract thrombus in a single session, from patients who present with Venous Thrombo-Embolism. Vetex Medical has developed the Vetex thrombectomy catheter as a platform technology for the venous vascular system targeting deep vein thrombosis, AV Fistula grafts and pulmonary embolism. Initially Vetex Medical will target patients with acute DVT in the ilio-femoral veins. The venous thrombectomy market has been underserved for many years but is currently one of the key drivers of the clot management market as clinical evidence and awareness increases.

Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.

Cognition Medical Corp. is a medical device company based in Cambridge, Massachusetts, focused on developing innovative therapy solutions for acute stroke patients. Incorporated in 2012, the company specializes in devices that remove blood clots from the brain through minimally invasive techniques, eliminating the need for surgery. Their technology allows for navigation through catheters within blood vessels to safely retrieve clots while also protecting the brain from potential over-oxygenation that can occur after blocked vessels are reopened. Cognition Medical aims to improve the safety and efficiency of stroke procedures, ultimately reducing brain damage and promoting healthier outcomes for patients. The company combines expertise across various fields, including engineering, biology, and interventional medicine, to advance its mission.

Fosmo Med is innovating in the field of intravenous (IV) solutions by utilizing Forward Osmosis (FO) technology, which enables the production of IV bags using any available water source at the point of care. This approach allows the bags to be shipped without water, significantly lowering shipping costs, extending product shelf life, and minimizing storage expenses while reducing the risk of leakage. The technology is particularly aimed at organizations involved in disaster relief, such as the Red Cross and Doctors Without Borders, as it facilitates the conversion of non-potable water into a sterile 0.9 percent saline solution without the need for electrical power. This advancement not only enhances the safety and sterility of IV fluids but also helps combat dehydration-related diseases, making it a valuable solution in emergency situations. Fosmo Med has a patent pending on this innovative technology.

MedAware Ltd specializes in developing solutions aimed at detecting and eliminating prescription errors to enhance patient safety and reduce healthcare costs. Founded in 2012 and headquartered in Raanana, Israel, the company utilizes advanced data analytics and machine learning algorithms to analyze extensive electronic medical records. Its offerings include the MedAS alerting system for real-time alerts on prescription errors, MedRIM for risk management support, MedQC for quality control assistance, and MedRAF to reduce alert fatigue. These tools enable healthcare providers, pharmacy benefit management companies, and pharmacy chains to leverage big data effectively, identify potential prescription errors related to drug interactions, dosages, and allergies, and ultimately improve patient outcomes.

Admetsys has developed a first-of-its-kind artificial pancreas for hospital and surgical care, leveraging adaptive learning algorithms and counterbalancing treatment of insulin and glucose. The system has undergone 3 successful FDA-approved clinical trials with 97% control between 80–125 mg/dl and zero incidents of low blood sugar.

Lightpoint Medical, Ltd., a medical device company, develops imaging technologies for cancer surgery. It develops Cerenkov Luminescence Imaging technology that detects cancer in real-time during surgery, and reduces the likelihood of cancer recurrence and the need for reoperation. Lightpoint Medical, Ltd. was formerly known as Artemis Diagnostics Ltd. and changed its name to Lightpoint Medical, Ltd. in January 2013. The company was founded in 2012 and is based in Rickmansworth, United Kingdom.

Diagnostic Photonics, Inc. specializes in advanced imaging technologies designed to aid physicians in the real-time assessment of tissue microstructure. Founded in 2008 and headquartered in Chicago, Illinois, the company has developed the Foresee Imaging System, which produces diffraction-corrected images to enhance tissue evaluation. The innovative imaging technology stems from research conducted at the Beckman Institute for Advanced Science and Technology at the University of Illinois, known for its interdisciplinary approach to scientific advancement.

IntelliDrain, Inc. is a medical device company commercializing a novel chest drainage technology. Backed by human clinical trials and based on original research, IntelliDrain technology provides clinicians with decision support for timely removal of chest tubes, as well as therapeutically guiding and promoting lung healing. Application of our technology enables patients to go home sooner, avoids complications, and saves healthcare costs.

Torix Medical has created the Innoflow device, a disruptive solution to treat urinary obstruction related to benign prostatic hyperplasia (BPH). This condition affects most men at some point in life and imposes a significant quality of life burden. Their device will provide durable symptom relief in a simple, office-based procedure using common flexible cystoscopy tools. This means that implantation is easier for the urologist and far less painful for the patient than with any other BPH device. They have a strong IP position, a 510(k) FDA pathway, established reimbursement precedents, and an extremely quick and capital-efficient path to market. They have achieved excellent cadaver results to demonstrate that the mechanism works. They’re now beginning animal studies and will get to first-in-man in late 2015.

Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices. Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development for new applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy.

Tampa Medical Innovations, Inc. (TaMI) is a Medical Device company working on an innovative portfolio of products. Thsy have partnered with some of the leading Clinical and Academic institutions in the country to commercialize their “untapped” Medical Devices. Their business model is to focus on simple Class I and II devices that are low cost, have large market potential and will monetize quickly for their investors.

ChemoFilter is developing a novel catheter device enables chemotherapy delivery in a targeted manner, reducing patient side effects and improving treatment efficacy. The ChemoFilter device filters chemotherapeutics from the bloodstream, preventing toxic drugs from leaving the tumor site. ChemoFilter’s first version will treat unresectable liver cancer, the 3rd leading cause of cancer death with over 600,000 new cases per year by working in tandem with trans-arterial chemoembolization (TACE), the current standard of care for this disease. ChemoFilter will save the healthcare system over $5,000 per patient, while increasing hospital and physician margins and improving patient care. ChemoFilter has potential worldwide sales of over $1 billion in liver cancer with the opportunity to expand into other cancers. A UCSF based startup, ChemoFilter is supported by seed grants from UCSF, Society of Interventional Radiology, and the prestigious NIH Small Business Technology Transfer (STTR) grant.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

ProDural is a new syringe which can make epidurals safer and more reliable. The patented inflating diaphragm at the syringe’s tip visually indicates the pressure drop on entry into the epidural space. The current loss of resistance technique relies on a subtle haptic feedback which can result in inadvertent puncture of the dura space. Trainee anaesthetists puncture in 1/5 patients and may take up to 75 epidurals before they are proficient. Their syringe device can reduce complications in the 12M epidurals that take place annually in the US alone. The collapsing diaphragm which indicates epidural entry can be used in any clinical setting involving percutaneous needle puncture.

At Hemova Medical, we seek innovative solutions towards vascular access. A patient's access is their lifeline, and currently available options inadequately address the need for a safe, reliable and robust means for hemodialysis administration

Liberate Medical, LLC is a medical device company focused on improving the treatment of patients with chronic obstructive pulmonary disease (COPD) by developing innovative technologies. Founded in 2013 and based in Crestwood, Kentucky, the company has created VentFree, a system that utilizes non-invasive neuromuscular electrical stimulation to contract abdominal wall muscles in sync with a patient’s breathing. This approach aims to minimize disuse atrophy of these muscles, potentially decreasing the duration of mechanical ventilation required for adult patients. By enhancing respiratory muscle function, Liberate Medical seeks to improve patient outcomes and reduce healthcare costs associated with pulmonary disorders.

As of October 22, 2019, NeuroRecovery Technologies, Inc. was acquired by G-Therapeutics B.V. NeuroRecovery Technologies, Inc., a medical device company, develops therapeutic systems for individuals suffering from paralysis. Its products develop external and implantable spinal cord neuromodulation systems for restoring function/enabling movement in paralysis patients. The company was incorporated in 2013 and is based in San Juan Capistrano, California.

Headquartered in Silicon Valley, NeuroSyntek Modeling & Manufacturing is rapidly emerging as a leader in the field of regenerative medicine, a group of biomedical approaches to clinical therapies that involve the use of stem cells to replace or regenerate human cells, tissues or organs to restore or establish normal function. NeuroSyntek is entering human trials on amyotrophic lateral sclerosis (ALS) with a uniquely powerful personalized medicine solution and is able to help with other diseases - such as stroke, brain trauma, Parkinson's, diabetes - to ophthalmology, orthopedic and cosmetic applications. Leveraging their semiconductor platform they bring major cost and automation benefits into stem cell therapy. NeuroSyntek technology allows for autologous mono-phenotype stem-cells cultures to be screened, grown and differentiated for transplantation without the risk of transformation into tumors. They enable this revolutionary approach through the use of their proprietary StemOptimizer platform and behavioral models. This powerful combination allows for unprecedented control over the cellular behavior, in vitro, for precise, automated and continuous cell culture monitoring and manipulation. The StemOptimizer is build around an advanced System-on-Chip architecture and their proprietary silicon extra-cellular sensor. This design allows for an adaptive, dynamically reconfigurable, and able to learn architecture that is the anchor for their aggressive and broad-based product roadmap. Their disruptive technology will help to optimize the massively inefficient $6 trillion healthcare market by dramatically driving down costs and providing effective solutions for stem-cell therapies. In Phase I of their product roadmap they are addressing the $30B+ stem cells market.

The company promotes MoPill--short for Gastrointestinal Motility Pill--as an affordable, minimally invasive and radiation-free way to observe peristalsis and forward and backward movement in the GI tract. According to its website, MoPill can diagnose and monitor gastrointestinal conditions such as dyspepsia (indigestion), diabetic gastroparesis and intestinal obstruction, the company said in a statement in March last year.